# SEC and FDA Sign Three-Year Information-Sharing Agreement to Curb Insider Trading

The U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) have signed a three-year agreement to strengthen cooperation and share information. The deal is intended to improve each agency’s regulatory and enforcement missions. According to the announcement, the pact is a signal to the market that regulators are stepping up efforts against insider trading.

The agreement formalizes a framework for exchanging data and coordinating investigations. It allows the SEC to access FDA information that could help detect illegal trading based on non-public regulatory decisions. The FDA, in turn, can draw on SEC expertise to identify potential misconduct related to its own oversight activities.

## Relevance to the Life Sciences

The biotech and pharmaceutical industries are particularly sensitive to FDA actions. Drug approval decisions, clinical trial results, and inspection outcomes can move stock prices sharply. Insider trading based on advance knowledge of such events has been a recurring concern. The information-sharing agreement gives the SEC a direct channel to FDA data, making it easier to spot suspicious trading patterns tied to regulatory milestones. For life-science companies, the deal signals that regulators are watching more closely for illegal activity that undermines market integrity.

Source: [original report](https://www.fiercebiotech.com/biotech/sec-fda-sign-info-sharing-agreement-signal-market-insider-trading)